XBIO MEXC RealStocks
Own real XBIO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 12:21:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Xenetic Biosciences, Inc. (XBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.62, with a market capitalization of $4.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $4.94. This page covers its latest market performance, valuation, price trends and company information.
$4.22M | |
$1.86 | |
$1.93 | |
$1.62 | |
$1.87 | |
361.00 | |
75.28K | |
-- | |
$4.94 | |
$1.58 | |
-- | |
-- |
Xenetic Biosciences, Inc. (XBIO) is trading at $1.62 in pre-market trading as of 2026-11-12 12:02:00, down 13.41% ($0.25) from the previous close of $1.87
Pre-market trading shows how investors are pricing XBIO before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Xenetic Biosciences, Inc. (XBIO) moved from $2.08 to $1.62, representing a decline of 22.31% ($0.46).
The stock traded between $1.62 and $2.16 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 10.79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.1%
XBIO is currently trading at $1.62, placing it 1.1% of the way from its 52-week low of $1.58 to its 52-week high of $4.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Xenetic Biosciences, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Xenetic Biosciences, Inc. (XBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to XBIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between XBIO shares and USD.
XBIO Shares to USD
1.00 XBIO shares = 1.616 USD
Calculations are estimates based on the latest available price and are for reference only.